Rett Syndrome: Crossing the Threshold to Clinical Translation

Trends in Neurosciences

Volumn 39, Issue 2, 2016, Pages 100-113

  Katz, David M ^a   Bird, Adrian ^b   Coenraads, Monica ^c   Gray, Steven J ^d   Menon, Debashish U ^d   Philpot, Benjamin D ^d   Tarquinio, Daniel C ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Rett Syndrome Research Trust   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Clinical trials; Epigenetics; Gene therapy; MECP2; Neurodevelopmental disorders; Preclinical models

Indexed keywords

BIOLOGICAL MARKER; BRAIN MONOAMINE; GROWTH FACTOR; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER;

BIOTECHNOLOGY; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG TARGETING; EPIGENETICS; GENE DOSAGE; GENE THERAPY; GENETICS; GENOME ANALYSIS; HISTORY; HUMAN; NERVE CELL; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RARE DISEASE; RETT SYNDROME; REVIEW; STUDY DESIGN; UNITED STATES; X CHROMOSOME; ANIMAL; GENETIC EPIGENESIS; MUTATION; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HUMANS; MUTATION; RETT SYNDROME; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84959056410     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.12.008     Document Type: Review

References (124)

1. Amir R.E., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
2. Katz D.M., et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis. Model. Mech. 2012, 5:733-745.
3. Gadalla K.K., et al. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem. J. 2011, 439:1-14.
4. Lombardi L.M., et al. MECP2 disorders: from the clinic to mice and back. J. Clin. Invest. 2015, 125:2914-2923.
5. Weng S.M., et al. Rett syndrome: from bed to bench. Pediatr. Neonatol. 2011, 52:309-316.
6. Pozzo-Miller L., et al. Rett Syndrome: reaching for clinical trials. Neurotherapeutics 2015, 12:631-640.
7. Ricceri L., et al. Rett syndrome treatment in mouse models: searching for effective targets and strategies. Neuropharmacology 2013, 68:106-115.
8. Chapleau C.A., et al. Recent progress in Rett Syndrome and MeCP2 dysfunction: assessment of potential treatment options. Future Neurol. 2013, Published online January 1, 2013. 10.2217/fnl.12.79.
9. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
10. Laurvick C.L., et al. Rett syndrome in Australia: a review of the epidemiology. J. Pediatr. 2006, 148:347-352.
11. Neul J.L., et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008, 70:1313-1321.
12. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:61-65.
13. Neul J.L. The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues Clin. Neurosci. 2012, 14:253-262.
14. Rett A. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien. Med. Wochenschr. 1966, 116:723-726.
15. Neul J.L., et al. Developmental delay in Rett syndrome: data from the natural history study. J. Neurodev. Disord. 2014, 6:20.
16. Wandin H., et al. Communication intervention in Rett syndrome: a survey of speech language pathologists in Swedish health services. Disabil. Rehabil. 2015, 37:1324-1333.
17. Akbarian S. The neurobiology of Rett syndrome. Neuroscientist 2003, 9:57-63.
18. Guy J., et al. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
19. Shepherd G.M., Katz D.M. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr. Opin. Neurobiol. 2011, 21:827-833.
20. Armstrong D.D. Neuropathology of Rett syndrome. J. Child Neurol. 2005, 20:747-753.
21. Chapleau C.A., et al. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol. Dis. 2009, 35:219-233.
22. Samaco R.C., et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21966-21971.
23. Johnston M.V., et al. Neurobiology of Rett syndrome. Neuropediatrics 1995, 26:119-122.
24. Blue M.E., et al. Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann. Neurol. 1999, 45:541-545.
25. Wenk G.L., et al. Altered neurochemical markers in Rett's syndrome. Neurology 1991, 41:1753-1756.
26. Cohen S., Greenberg M.E. Communication between the synapse and the nucleus in neuronal development, plasticity, and disease. Annu. Rev. Cell Dev. Biol. 2008, 24:183-209.
27. Cheval H., et al. Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows. Hum. Mol. Genet. 2012, 21:3806-3814.
28. McGraw C.M., et al. Adult neural function requires MeCP2. Science 2011, 333:186.
29. McGann J.C., et al. Astrocytes conspire with neurons during progression of neurological disease. Curr. Opin. Neurobiol. 2012, 22:850-858.
30. Blackman M.P., et al. A critical and cell-autonomous role for MeCP2 in synaptic scaling up. J. Neurosci. 2012, 32:13529-13536.
31. Dani V.S., Nelson S.B. Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. J. Neurosci. 2009, 29:11263-11270.
32. Taneja P., et al. Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J. Neurosci. 2009, 29:12187-12195.
33. He L.J., et al. Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. Nat. Commun. 2014, 5:5036.
34. Kron M., et al. Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J. Neurosci. 2012, 32:13860-13872.
35. Dani V.S., et al. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12560-12565.
36. Durand S., et al. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 2012, 76:1078-1090.
37. Wood L., Shepherd G.M. Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in a mutant mouse model of Rett syndrome. Neurobiol. Dis. 2010, 38:281-287.
38. Sceniak M.P., et al. Mechanisms of functional hypoconnectivity in the medial prefrontal cortex of Mecp2 null mice. Cereb. Cortex 2015, Published online February 7, 2015. 10.1093/cercor/bhv002.
39. Kline D.D., et al. Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J. Neurosci. 2010, 30:5303-5310.
40. Abdala A.P., et al. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18208-18213.
41. Calfa G., et al. Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice. Hippocampus 2015, 25:159-168.
42. Zhang L., et al. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 2008, 18:294-309.
43. Luikenhuis S., et al. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6033-6038.
44. Van Esch H., et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 2005, 77:442-453.
45. del Gaudio D., et al. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet. Med. 2006, 8:784-792.
46. Meins M., et al. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J. Med. Genet. 2005, 42:e12.
47. Heckman L.D., et al. Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice. Elife 2014, 3:02676.
48. Huang H.S., et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012, 481:185-189.
49. Meng L., et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 2015, 518:409-412.
50. Yeung B.H., et al. Evolution and roles of stanniocalcin. Mol. Cell. Endocrinol. 2012, 349:272-280.
51. Bhatnagar S., et al. Genetic and pharmacological reactivation of the mammalian inactive X chromosome. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12591-12598.
52. Gray S.J., et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 2011, 19:1058-1069.
53. Duque S., et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009, 17:1187-1196.
54. Foust K.D., et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
55. Gadalla K.K., et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol. Ther. 2013, 21:18-30.
56. Garg S.K., et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J. Neurosci. 2013, 33:13612-13620.
57. Savic N., Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl. Res. 2015, Published online September 26, 2015. 10.1016/j.trsl.2015.09.008.
58. Deffit S.N., Hundley H.A. To edit or not to edit: regulation of ADAR editing specificity and efficiency. RNA 2015, Published online November 26, 2015. 10.1002/wrna.1319.
59. Keeling K.M., et al. Therapeutics based on stop codon readthrough. Annu. Rev. Genomics Hum. Genet. 2014, 15:371-394.
60. Brendel C., et al. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J. Mol. Med. (Berl) 2011, 89:389-398.
61. Ricceri L., et al. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 2008, 19:501-517.
62. Ramirez J.M., et al. Breathing challenges in Rett Syndrome: lessons learned from humans and animal models. Respir. Physiol. Neurobiol. 2013, 189:280-287.
63. Katz D.M., et al. Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth. Respir. Physiol. Neurobiol. 2009, 168:101-108.
64. Patrizi A., et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett Syndrome phenotype. Biol. Psychiatry 2015, Published online August 24, 2015. 10.1016/j.biopsych.2015.08.018.
65. Seamans J. Losing inhibition with ketamine. Nat. Chem. Biol. 2008, 4:91-93.
66. Jin Y.H., et al. Ketamine differentially blocks sensory afferent synaptic transmission in medial nucleus tractus solitarius (mNTS). Anesthesiology 2003, 98:121-132.
67. Lepack A.E., et al. BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 2015, Published online October 31, 2014. 10.1093/ijnp/pyu033.
68. Kavalali E.T., Monteggia L.M. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am. J. Psychiatry 2012, 169:1150-1156.
69. Ricciardi S., et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 2011, 20:1182-1196.
70. Dwyer J.M., Duman R.S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol. Psychiatry 2013, 73:1189-1198.
71. Bogaerts J., et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur. J. Cancer 2015, 51:271-281.
72. Tudur Smith C., et al. Methodology of clinical trials for rare diseases. Best Pract. Res. Clin. Rheumatol. 2014, 28:247-262.
73. van der Lee J.H., et al. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J. Clin. Epidemiol. 2008, 61:324-330.
74. Bauer P., Brannath W. The advantages and disadvantages of adaptive designs for clinical trials. Drug Discov. Today 2004, 9:351-357.
75. Gerss J.W., Kopcke W. Clinical trials and rare diseases. Adv. Exp. Med. Biol. 2010, 686:173-190.
76. Takeuchi F., et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. J. Neurol. 2013, 260:3023-3029.
77. Blat Y., Blat S. Drug discovery of therapies for Duchenne muscular dystrophy. J. Biomol. Screen. 2015, 20:1189-1203.
78. Monros E., et al. Rett syndrome in Spain: mutation analysis and clinical correlations. Brain Dev. 2001, 23(Suppl. 1):S251-S253.
79. FitzGerald P.M., et al. Rett syndrome and associated movement disorders. Mov. Disord. 1990, 5:195-202.
80. Cuddapah V.A., et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J. Med. Genet. 2014, 51:152-158.
81. Motil K.J., et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 2012, 55:292-298.
82. Glaze D.G., et al. Epilepsy and the natural history of Rett syndrome. Neurology 2010, 74:909-912.
83. Percy A.K., et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann. Neurol. 1994, 35:464-470.
84. Glaze D.G., et al. A study of the treatment of Rett syndrome with folate and betaine. J. Child Neurol. 2009, 24:551-556.
85. Khwaja O.S., et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:4596-4601.
86. Hagebeuk E.E., et al. Folinic acid supplementation in Rett syndrome patients does not influence the course of the disease: a randomized study. J. Child Neurol. 2012, 27:304-309.
87. Kesselheim A.S., Gagne J.J. Strategies for postmarketing surveillance of drugs for rare diseases. Clin. Pharmacol. Ther. 2014, 95:265-268.
88. Hampson L.V., et al. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. PLoS ONE 2015, 10:e0120981.
89. Lewis J.D., et al. Purification, sequence and cellular localisation of a novel chromosomal protein that binds to methylated DNA. Cell 1992, 69:905-914.
90. Nan X., et al. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 1993, 21:4886-4892.
91. Skene P.J., et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37:457-468.
92. Baubec T., et al. Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell 2013, 153:480-492.
93. Guo J.U., et al. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat. Neurosci. 2014, 17:215-222.
94. Gabel H.W., et al. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature 2015, 522:89-93.
95. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
96. Valinluck V., et al. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004, 32:4100-4108.
97. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25:1010-1022.
98. Chen L., et al. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:5509-5514.
99. Ballestar E., et al. Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 2000, 39:7100-7106.
100. Lyst M.J., et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 2013, 16:898-902.
101. Lyst M.J., Bird A. Rett syndrome: a complex disorder with simple roots. Nat. Rev. Genet. 2015, 16:261-275.
102. Nan X., et al. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
103. Nan X., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
104. Ben-Shachar S., et al. Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 2009, 18:2431-2442.
105. Chahrour M., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
106. Li Y., et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 2013, 13:446-458.
107. Yazdani M., et al. Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. Stem Cells 2012, 30:2128-2139.
108. Cheng T.L., et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev. Cell 2014, 28:547-560.
109. Maunakea A.K., et al. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 2013, 23:1256-1269.
110. Horike S., et al. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 2005, 37:31-40.
111. Georgel P.T., et al. Chromatin compaction by human MeCP2: Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 2003, 278:32181-32188.
112. Ausio J., et al. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol. Med. 2014, 20:487-498.
113. Haas R.H., et al. Therapeutic effects of a ketogenic diet in rett syndrome. Am. J. Med. Genet. 1986, 25:225-246.
114. Zappella M. A double blind trial of bromocriptine in the Rett syndrome. Brain Dev. 1990, 12:148-150.
115. Ellaway C., et al. Rett syndrome: randomized controlled trial of L-carnitine. J. Child Neurol. 1999, 14:162-167.
116. Ellaway C.J., et al. Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001, 23(Suppl. 1):S85-S89.
117. Temudo T., et al. Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment. Brain Dev. 2009, 31:46-51.
118. Hagebeuk E.E., et al. Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients. J. Child Neurol. 2011, 26:718-723.
119. Freilinger M., et al. Effects of creatine supplementation in Rett syndrome: a randomized, placebo-controlled trial. J. Dev. Behav. Pediatr. 2011, 32:454-460.
120. Leoncini S., et al. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011, 16:145-153.
121. Signorini C., et al. F(4)-neuroprostanes mediate neurological severity in Rett syndrome. Clin. Chim. Acta 2011, 412:1399-1406.
122. Pini G., et al. IGF1 as a potential treatment for Rett Syndrome: safety assessment in six Rett patients. Autism Res. Treat. 2012, 2012:679801.
123. De Felice C., et al. Partial rescue of Rett syndrome by omega-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012, 7:447-458.
124. Maffei S., et al. Effects of omega-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome. Mediators of Inflamm. 2014, 2014:983178.